Xilio Development Stock Performance
| XLO Stock | USD 0.63 0.01 1.61% |
The firm maintains a market beta of 0.79, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Xilio Development's returns are expected to increase less than the market. However, during the bear market, the loss of holding Xilio Development is expected to be smaller as well. At this point, Xilio Development has a negative expected return of -0.4%. Please make sure to check out Xilio Development's total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Xilio Development performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Xilio Development has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in February 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Best data tools to analyze Xilio Therapeutics Inc. stock - July 2025 Selloffs Verified Momentum Stock Ideas - newser.com | 11/04/2025 |
2 | Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer 40th Annual Meeting | 11/07/2025 |
3 | Xilio Therapeutics GAAP EPS of -0.11 misses by 0.08, revenue of 19.07M beats by 0.43M | 11/13/2025 |
4 | Xilio Therapeutics Announces Earnings Results, Hits Expectations | 11/17/2025 |
5 | Disposition of 700000 shares by Russo Rene of Xilio Development at 2.785 subject to Rule 16b-3 | 11/21/2025 |
6 | Acquisition by Christopher Frankenfield of 925000 shares of Xilio Development at 0.841 subject to Rule 16b-3 | 11/25/2025 |
7 | Acquisition by Christopher Frankenfield of 117000 shares of Xilio Development at 1.5 subject to Rule 16b-3 | 11/28/2025 |
8 | Is Xilio Therapeutics Inc. stock supported by strong fundamentals - Profit Target High Conviction Investment Ideas - ulpravda.ru | 12/18/2025 |
9 | Acquisition by Russo Rene of 1500258 shares of Xilio Development at 0.841 subject to Rule 16b-3 | 12/31/2025 |
10 | Disposition of 7030 shares by Christopher Frankenfield of Xilio Development at 0.6432 subject to Rule 16b-3 | 01/02/2026 |
11 | Xilio Therapeutics Extends Cash Runway Into 2027 - The Globe and Mail | 01/06/2026 |
12 | Xilio Therapeutics reverse split vote to keep listing - Stock Titan | 01/16/2026 |
| Begin Period Cash Flow | 46.3 M | |
| Total Cashflows From Investing Activities | -36 K |
Xilio Development Relative Risk vs. Return Landscape
If you would invest 83.00 in Xilio Development on October 27, 2025 and sell it today you would lose (20.00) from holding Xilio Development or give up 24.1% of portfolio value over 90 days. Xilio Development is generating negative expected returns assuming volatility of 2.9839% on return distribution over 90 days investment horizon. In other words, 26% of stocks are less volatile than Xilio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Xilio Development Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xilio Development's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xilio Development, and traders can use it to determine the average amount a Xilio Development's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Xilio Development is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xilio Development by adding Xilio Development to a well-diversified portfolio.
Xilio Development Fundamentals Growth
Xilio Stock prices reflect investors' perceptions of the future prospects and financial health of Xilio Development, and Xilio Development fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xilio Stock performance.
| Return On Equity | -9.08 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.84) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | (54.03 M) | ||||
| Shares Outstanding | 67.54 M | ||||
| Price To Book | 5.87 X | ||||
| Price To Sales | 1.34 X | ||||
| Revenue | 6.34 M | ||||
| Gross Profit | 26.26 M | ||||
| EBITDA | (58 M) | ||||
| Net Income | (58.24 M) | ||||
| Cash And Equivalents | 159.41 M | ||||
| Cash Per Share | 5.82 X | ||||
| Total Debt | 8.14 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 9.17 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (18.38 M) | ||||
| Earnings Per Share | (0.61) X | ||||
| Market Capitalization | 42.47 M | ||||
| Total Asset | 71.08 M | ||||
| Retained Earnings | (383.75 M) | ||||
| Working Capital | 32.97 M | ||||
About Xilio Development Performance
By examining Xilio Development's fundamental ratios, stakeholders can obtain critical insights into Xilio Development's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Xilio Development is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.94) | (0.99) | |
| Return On Capital Employed | (1.24) | (1.31) | |
| Return On Assets | (0.94) | (0.99) | |
| Return On Equity | (3.81) | (3.62) |
Things to note about Xilio Development performance evaluation
Checking the ongoing alerts about Xilio Development for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xilio Development help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xilio Development generated a negative expected return over the last 90 days | |
| Xilio Development has some characteristics of a very speculative penny stock | |
| Xilio Development has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 6.34 M. Reported Net Loss for the year was (58.24 M) with profit before taxes, overhead, and interest of 26.26 M. | |
| Xilio Development has about 159.41 M in cash with (18.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Xilio Development has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: Xilio Therapeutics reverse split vote to keep listing - Stock Titan |
- Analyzing Xilio Development's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xilio Development's stock is overvalued or undervalued compared to its peers.
- Examining Xilio Development's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xilio Development's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xilio Development's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xilio Development's stock. These opinions can provide insight into Xilio Development's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xilio Development. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xilio Development. If investors know Xilio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xilio Development listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth 7.425 | Return On Assets | Return On Equity |
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xilio Development's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.